PL2750707T3 - Pegylowane liposomy do dostarczania rna kodującego immunogen - Google Patents
Pegylowane liposomy do dostarczania rna kodującego immunogenInfo
- Publication number
- PL2750707T3 PL2750707T3 PL12769787T PL12769787T PL2750707T3 PL 2750707 T3 PL2750707 T3 PL 2750707T3 PL 12769787 T PL12769787 T PL 12769787T PL 12769787 T PL12769787 T PL 12769787T PL 2750707 T3 PL2750707 T3 PL 2750707T3
- Authority
- PL
- Poland
- Prior art keywords
- immunogen
- delivery
- encoding rna
- pegylated liposomes
- pegylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161529878P | 2011-08-31 | 2011-08-31 | |
| EP12769787.8A EP2750707B1 (en) | 2011-08-31 | 2012-08-31 | Pegylated liposomes for delivery of immunogen-encoding rna |
| PCT/US2012/053391 WO2013033563A1 (en) | 2011-08-31 | 2012-08-31 | Pegylated liposomes for delivery of immunogen-encoding rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2750707T3 true PL2750707T3 (pl) | 2019-05-31 |
Family
ID=47003206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12769787T PL2750707T3 (pl) | 2011-08-31 | 2012-08-31 | Pegylowane liposomy do dostarczania rna kodującego immunogen |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20140255472A1 (pl) |
| EP (2) | EP3508220A1 (pl) |
| JP (1) | JP2014525461A (pl) |
| CN (1) | CN103974719A (pl) |
| AU (1) | AU2012301715B2 (pl) |
| BR (1) | BR112014004607A2 (pl) |
| CA (1) | CA2846043A1 (pl) |
| CY (1) | CY1121122T1 (pl) |
| DK (1) | DK2750707T3 (pl) |
| ES (1) | ES2705498T3 (pl) |
| HR (1) | HRP20190032T1 (pl) |
| HU (1) | HUE041800T2 (pl) |
| LT (1) | LT2750707T (pl) |
| MX (1) | MX366055B (pl) |
| PL (1) | PL2750707T3 (pl) |
| PT (1) | PT2750707T (pl) |
| RU (1) | RU2628705C2 (pl) |
| SG (2) | SG11201400250UA (pl) |
| SI (1) | SI2750707T1 (pl) |
| TR (1) | TR201900264T4 (pl) |
| WO (1) | WO2013033563A1 (pl) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2591114T (pt) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Imunização de mamíferos de grande porte com doses baixas de arn |
| BR112013000392B8 (pt) | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
| US20130171241A1 (en) | 2010-07-06 | 2013-07-04 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK4066819T3 (da) | 2010-08-31 | 2023-04-24 | Glaxosmithkline Biologicals Sa | Små liposomer til levering af RNA, der koder for immunogen |
| ES2935009T3 (es) | 2010-08-31 | 2023-03-01 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
| US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
| AU2011316707A1 (en) | 2010-10-11 | 2013-05-09 | Novartis Ag | Antigen delivery platforms |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| SI2717893T1 (sl) | 2011-06-08 | 2019-10-30 | Translate Bio Inc | Sestavki lipidnih nanodelcev in postopki za dostavo mRNA |
| US11896636B2 (en) * | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| IN2014KN02929A (pl) * | 2012-07-06 | 2015-05-08 | Novartis Ag | |
| EP2885419A4 (en) | 2012-08-14 | 2016-05-25 | Moderna Therapeutics Inc | ENZYMES AND POLYMERASES FOR RNA SYNTHESIS |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| CN109045294A (zh) * | 2013-01-10 | 2018-12-21 | 思齐乐 | 流感病毒免疫原性组合物及其应用 |
| WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| ES2774968T3 (es) | 2013-12-19 | 2020-07-23 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP3122774B1 (en) | 2014-03-25 | 2020-11-04 | Yale University | Uses of parasite macrophage migration inhibitory factors |
| US9532986B2 (en) | 2014-04-08 | 2017-01-03 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| CA2943201A1 (en) | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomes that form drug nanocrystals after freeze-thaw |
| SG11201608798YA (en) | 2014-04-23 | 2016-11-29 | Modernatx Inc | Nucleic acid vaccines |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3352785A1 (en) * | 2015-09-23 | 2018-08-01 | Massachusetts Institute Of Technology | Compositions and methods for modified dendrimer nanoparticle vaccine delivery |
| CA3001003A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| SI3718565T1 (sl) | 2015-10-22 | 2022-08-31 | Modernatx, Inc. | Cepiva za respiratorni virus |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| WO2017123315A2 (en) * | 2016-01-12 | 2017-07-20 | Aradigm Corporation | Nanocrystals formed in a microenvironment |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| BR112018073683A2 (pt) | 2016-05-18 | 2019-02-26 | Modernatx, Inc. | polinucleotídeos codificadores de relaxina |
| US10967057B2 (en) | 2016-06-02 | 2021-04-06 | Glaxosmithkline Biologicals S.A. | Zika viral antigen constructs |
| WO2017220099A1 (en) | 2016-06-24 | 2017-12-28 | Statens Serum Institut | Adjuvants with modified drainage properties |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018091540A1 (en) | 2016-11-17 | 2018-05-24 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| KR20190120233A (ko) * | 2017-02-01 | 2019-10-23 | 모더나티엑스, 인크. | Rna 암 백신 |
| AU2018234692B2 (en) | 2017-03-15 | 2022-06-02 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
| DK3596042T3 (da) | 2017-03-15 | 2022-04-11 | Modernatx Inc | Krystalformer af aminolipider |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| TW201907937A (zh) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | 阿爾法病毒新抗原載體 |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
| US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| JP7416686B2 (ja) | 2017-09-13 | 2024-01-17 | バイオエヌテック エスエー | 体細胞を再プログラムするためのｒｎａレプリコン |
| EP3681904A1 (en) | 2017-09-13 | 2020-07-22 | Biontech Cell&Gene Therapies GmbH | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| EP3720422A4 (en) * | 2017-12-06 | 2021-08-25 | NewSouth Innovations Pty Limited | LIPOSOMAL SYSTEM FOR DRUG DELIVERY |
| KR20200118029A (ko) | 2018-01-04 | 2020-10-14 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| EP3836963A2 (en) | 2018-08-17 | 2021-06-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions and uses thereof |
| CN113166783A (zh) | 2018-10-09 | 2021-07-23 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| EP3908328A1 (en) | 2019-01-10 | 2021-11-17 | BioNTech RNA Pharmaceuticals GmbH | Localized administration of rna molecules for therapy |
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN114072516A (zh) | 2019-05-30 | 2022-02-18 | 磨石生物公司 | 经修饰的腺病毒 |
| WO2020255014A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Recombinant interleukin 12 construct and uses thereof |
| EP3986454A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
| MA56533A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 |
| US20220305117A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| AU2020295807A1 (en) | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines |
| WO2021013798A1 (en) | 2019-07-21 | 2021-01-28 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
| MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
| EP3819377A1 (en) | 2019-11-08 | 2021-05-12 | Justus-Liebig-Universität Gießen | Circular rna and uses thereof for inhibiting rna-binding proteins |
| US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
| EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
| AU2021236068A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| CN115667530A (zh) | 2020-03-24 | 2023-01-31 | 世代生物公司 | 非病毒dna载体和其用于表达因子ix治疗剂的用途 |
| WO2021195218A1 (en) | 2020-03-24 | 2021-09-30 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| EP4135761A1 (en) | 2020-04-16 | 2023-02-22 | GlaxoSmithKline Biologicals S.A. | Sars cov-2 spike protein construct |
| AU2021286169A1 (en) | 2020-06-04 | 2023-01-19 | BioNTech SE | RNA replicon for versatile and efficient gene expression |
| WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| WO2022002783A1 (en) | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Adjuvants |
| JP2023533528A (ja) | 2020-07-08 | 2023-08-03 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｈｂｖに対するｒｎａレプリコンワクチン |
| AU2021314809A1 (en) | 2020-07-27 | 2023-02-23 | Anjarium Biosciences Ag | Compositions of DNA molecules, methods of making therefor, and methods of use thereof |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| EP4008785A1 (en) | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| EP4267593A2 (en) | 2020-12-23 | 2023-11-01 | GlaxoSmithKline Biologicals SA | Self-amplifying messenger rna |
| WO2022146654A1 (en) | 2020-12-28 | 2022-07-07 | Janssen Pharmaceuticals, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
| EP4032546A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4313152A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| CN117327270A (zh) * | 2021-04-08 | 2024-01-02 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| JP2024517427A (ja) | 2021-04-20 | 2024-04-22 | アンジャリウム バイオサイエンシズ エージー | アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法 |
| CA3216585A1 (en) | 2021-04-27 | 2022-11-03 | Nathaniel SILVER | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| EP4329884A1 (en) | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| WO2022248353A1 (en) | 2021-05-24 | 2022-12-01 | Glaxosmithkline Biologicals Sa | Adjuvants |
| WO2022259191A1 (en) | 2021-06-09 | 2022-12-15 | Glaxosmithkline Biologicals Sa | Release assay for determining potency of self-amplifying rna drug product and methods for using |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| WO2023021427A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
| CA3234214A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| CA3234396A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
| WO2023081526A1 (en) | 2021-11-08 | 2023-05-11 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
| WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2335393C (en) | 1998-07-20 | 2008-09-23 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| EP1818409A1 (en) * | 1999-09-09 | 2007-08-15 | CureVac GmbH | Transfer of mRNAusing polycationic compounds |
| CN1981873A (zh) | 2000-06-09 | 2007-06-20 | 莱古伦公司 | 制备微胶粒的方法和所述微胶粒的用途 |
| DE60139690D1 (de) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
| EP2277895B1 (en) | 2000-10-27 | 2013-08-14 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
| EP1423142A1 (en) | 2001-08-31 | 2004-06-02 | Chiron SRL. | Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins |
| JP4722481B2 (ja) | 2002-06-28 | 2011-07-13 | プロティバ バイオセラピューティクス リミテッド | リポソーム製造方法および装置 |
| US20100255002A1 (en) | 2003-06-26 | 2010-10-07 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
| EP1648500B1 (en) | 2003-07-31 | 2014-07-09 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for streptococcus pyogenes |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| DE602005012382D1 (de) | 2004-05-18 | 2009-03-05 | Alphavax Inc | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren |
| EP1781593B1 (en) * | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
| JP4796062B2 (ja) | 2004-06-07 | 2011-10-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質封入干渉ｒｎａ |
| CN101203529A (zh) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
| ES2595363T3 (es) | 2005-02-18 | 2016-12-29 | J. Craig Venter Institute, Inc. | Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli |
| AU2006235045A1 (en) | 2005-03-30 | 2006-10-19 | J. Craig Venter Institute, Inc. | Haemophilus influenzae type b |
| US8133973B2 (en) | 2005-05-12 | 2012-03-13 | Novartis Vaccines And Diagnostics, S.R.L. | Immunogenic compositions for Chlamydia trachomatis |
| JP2009515831A (ja) | 2005-10-25 | 2009-04-16 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物 |
| EP2035581B1 (en) * | 2006-06-21 | 2012-09-26 | The Scripps Research Institute | Dna composition against tumor stromal antigen fap and methods of use thereof |
| EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
| LT2494993T (lt) | 2007-05-04 | 2018-12-27 | Marina Biotech, Inc. | Aminorūgščių lipidai ir jų panaudojimas |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0717187D0 (en) | 2007-09-04 | 2007-10-17 | Novartis Ag | Compositions comprising yersinia pestis antigens |
| EP2224912B1 (en) * | 2008-01-02 | 2016-05-11 | TEKMIRA Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| ITMI20081249A1 (it) | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
| EP2268659A2 (en) | 2008-03-06 | 2011-01-05 | Novartis AG | Mutant forms of chlamydia htra |
| WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
| CA2751342C (en) * | 2009-01-29 | 2019-05-07 | Alnylam Pharmaceuticals, Inc. | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
| EP2510947B1 (en) | 2009-04-14 | 2016-02-10 | GlaxoSmithKline Biologicals SA | Compositions for immunising against Staphylococcus aureus |
| EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| CN105214080A (zh) | 2009-07-15 | 2016-01-06 | 诺华股份有限公司 | Rsv f蛋白组合物和其制作方法 |
| EP2467357B1 (en) * | 2009-08-20 | 2016-03-30 | Sirna Therapeutics, Inc. | Novel cationic lipids with various head groups for oligonucleotide delivery |
| EP2496260A1 (en) | 2009-11-04 | 2012-09-12 | Marina Biotech, Inc. | Activity generating delivery molecules |
| JP2013515693A (ja) * | 2009-12-23 | 2013-05-09 | ノバルティス アーゲー | 脂質、脂質組成物およびそれらの使用方法 |
| WO2011149733A2 (en) * | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
| BR112013000392B8 (pt) * | 2010-07-06 | 2022-10-04 | Novartis Ag | Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso |
| US20130171241A1 (en) | 2010-07-06 | 2013-07-04 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
| DK4066819T3 (da) * | 2010-08-31 | 2023-04-24 | Glaxosmithkline Biologicals Sa | Små liposomer til levering af RNA, der koder for immunogen |
| ES2935009T3 (es) | 2010-08-31 | 2023-03-01 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
| US8584462B2 (en) * | 2011-07-21 | 2013-11-19 | Kalex, Llc | Process and power system utilizing potential of ocean thermal energy conversion |
-
2012
- 2012-08-31 EP EP18201799.6A patent/EP3508220A1/en active Pending
- 2012-08-31 LT LTEP12769787.8T patent/LT2750707T/lt unknown
- 2012-08-31 US US14/240,020 patent/US20140255472A1/en not_active Abandoned
- 2012-08-31 SG SG11201400250UA patent/SG11201400250UA/en unknown
- 2012-08-31 ES ES12769787T patent/ES2705498T3/es active Active
- 2012-08-31 WO PCT/US2012/053391 patent/WO2013033563A1/en active Application Filing
- 2012-08-31 RU RU2014112220A patent/RU2628705C2/ru active
- 2012-08-31 SI SI201231501T patent/SI2750707T1/sl unknown
- 2012-08-31 TR TR2019/00264T patent/TR201900264T4/tr unknown
- 2012-08-31 EP EP12769787.8A patent/EP2750707B1/en not_active Revoked
- 2012-08-31 JP JP2014528651A patent/JP2014525461A/ja active Pending
- 2012-08-31 CN CN201280052386.XA patent/CN103974719A/zh active Pending
- 2012-08-31 DK DK12769787.8T patent/DK2750707T3/en active
- 2012-08-31 AU AU2012301715A patent/AU2012301715B2/en active Active
- 2012-08-31 MX MX2014002203A patent/MX366055B/es active IP Right Grant
- 2012-08-31 HU HUE12769787A patent/HUE041800T2/hu unknown
- 2012-08-31 PL PL12769787T patent/PL2750707T3/pl unknown
- 2012-08-31 SG SG10201602456WA patent/SG10201602456WA/en unknown
- 2012-08-31 BR BR112014004607A patent/BR112014004607A2/pt not_active Application Discontinuation
- 2012-08-31 PT PT12769787T patent/PT2750707T/pt unknown
- 2012-08-31 CA CA 2846043 patent/CA2846043A1/en active Pending
-
2019
- 2019-01-04 HR HRP20190032TT patent/HRP20190032T1/hr unknown
- 2019-01-15 CY CY191100050T patent/CY1121122T1/el unknown
- 2019-12-16 US US16/714,877 patent/US20200113830A1/en not_active Abandoned
-
2023
- 2023-02-27 US US18/114,434 patent/US20240016736A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012301715A1 (en) | 2014-03-13 |
| MX366055B (es) | 2019-06-26 |
| US20240016736A1 (en) | 2024-01-18 |
| SI2750707T1 (sl) | 2019-02-28 |
| SG11201400250UA (en) | 2014-03-28 |
| MX2014002203A (es) | 2014-05-30 |
| BR112014004607A2 (pt) | 2017-03-21 |
| AU2012301715B2 (en) | 2017-08-24 |
| RU2628705C2 (ru) | 2017-08-21 |
| HRP20190032T1 (hr) | 2019-02-22 |
| DK2750707T3 (en) | 2019-02-11 |
| WO2013033563A1 (en) | 2013-03-07 |
| EP2750707B1 (en) | 2018-10-24 |
| SG10201602456WA (en) | 2016-04-28 |
| CY1121122T1 (el) | 2019-12-11 |
| TR201900264T4 (tr) | 2019-02-21 |
| EP3508220A1 (en) | 2019-07-10 |
| US20140255472A1 (en) | 2014-09-11 |
| RU2014112220A (ru) | 2015-10-10 |
| US20200113830A1 (en) | 2020-04-16 |
| CN103974719A (zh) | 2014-08-06 |
| ES2705498T3 (es) | 2019-03-25 |
| JP2014525461A (ja) | 2014-09-29 |
| PT2750707T (pt) | 2019-01-23 |
| EP2750707A1 (en) | 2014-07-09 |
| LT2750707T (lt) | 2019-01-10 |
| HUE041800T2 (hu) | 2019-05-28 |
| CA2846043A1 (en) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190032T1 (hr) | Pegilirani liposomi, namijenjeni unosu rna koja kodira imunogen | |
| RS63329B1 (sr) | Pegilovani lipozomi za isporuku rnk koja kodira imunogen | |
| HUE059214T2 (hu) | Kis liposzómák immunogént kódoló RNA bejuttatására |